CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults

By Reuters News

Nov 12 (Reuters) - Takeda Pharmaceutical Company Limited 4502.T:

  • TAKEDA: ORZEYFUL CIV NOW AVAILABLE IN U.S. BY PRESCRIPTION FOR TREATMENT OF NARCOLEPSY TYPE 1 IN ADULTS

  • TAKEDA: U.S. WHOLESALE ACQUISITION COST FOR ORZEYFUL $16,500 PER 60-TABLET BOTTLE, WITH SAME PRICE ACROSS ALL THREE STRENGTHS

Further company coverage: 4502.T

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk